Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline to Use Inpharmatica s ADME Technology

NEW YORK, March 22 (GenomeWeb News) - Inpharmatica has made its ADME (absorption, distribution, metabolism, and excretion) technology available to GlaxoSmithKline, the company said today.

 

Under the agreement, Inpharmatica, based in London, will apply its ADME technology to a number of GSK's drug discovery programs in the UK and in Europe.

 

Inpharmatica's ADME technology is part of its PharmaCarta chemogenomics platform that links genomic and proteomics data with chemistry data. The company acquired ADME technology last June from ArQule.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.